JPMorgan Chase & Co. downgraded shares of Phreesia (NYSE:PHR – Free Report) from a neutral rating to an underweight rating in a report released on Wednesday, Marketbeat Ratings reports. They currently have $13.00 target price on the stock.
A number of other brokerages have also recently commented on PHR. Wells Fargo & Company increased their price objective on shares of Phreesia from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Thursday, September 3rd. Canaccord Genuity Group restated a “buy” rating and set a $16.00 target price on shares of Phreesia in a research report on Thursday, September 3rd. Wall Street Zen downgraded shares of Phreesia from a “buy” rating to a “hold” rating in a report on Saturday, October 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price target on shares of Phreesia in a report on Monday, August 31st. Finally, Robert W. Baird increased their price target on shares of Phreesia from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Friday, September 4th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Phreesia has a consensus rating of “Hold” and an average price target of $13.87.
Check Out Our Latest Stock Report on PHR
Phreesia Stock Up 0.7%
Phreesia stock opened at $12.71 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a market capitalization of $788.60 million, a price-to-earnings ratio of 42.07 and a beta of 0.75. Phreesia has a fifty-two week low of $7.77 and a fifty-two week high of $22.58. The stock’s fifty day moving average is $11.24 and its two-hundred day moving average is $10.83.
Phreesia (NYSE:PHR – Get Free Report) last announced its quarterly earnings results on Wednesday, September 2nd. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.06). The firm had revenue of $129.46 million during the quarter, compared to analysts’ expectations of $129.06 million. Phreesia had a net margin of 2.06% and a return on equity of 5.22%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.01 EPS. Analysts predict that Phreesia will post 0.33 EPS for the current fiscal year.
Insider Activity
In other news, General Counsel Allison C. Hoffman sold 6,662 shares of the company’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $10.08, for a total value of $67,152.96. Following the sale, the general counsel directly owned 266,574 shares in the company, valued at $2,687,065.92. This represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its stake in shares of Phreesia by 1,119.8% during the 1st quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company’s stock worth $27,000 after purchasing an additional 3,001 shares during the last quarter. New York State Teachers Retirement System acquired a new position in shares of Phreesia in the first quarter valued at approximately $44,000. Allworth Financial LP acquired a new position in shares of Phreesia in the second quarter valued at approximately $58,000. Essential Partners LLC lifted its stake in shares of Phreesia by 2,016.6% during the first quarter. Essential Partners LLC now owns 9,313 shares of the company’s stock valued at $78,000 after buying an additional 8,873 shares during the period. Finally, Inceptionr LLC purchased a new position in shares of Phreesia during the first quarter valued at approximately $88,000. Institutional investors and hedge funds own 92.10% of the company’s stock.
Phreesia Company Profile
Phreesia, Inc. provides software and services that help healthcare organizations manage interactions with patients. Its platform supports tasks such as patient registration and intake, appointment scheduling, payments, and communications before and after visits. Phreesia’s tools include digital and mobile options for completing forms and sharing information, as well as services designed to help providers engage patients and streamline administrative workflows. The company serves healthcare providers and organizations primarily in the United States.
Further Reading
- Five stocks we like better than Phreesia
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.
